PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.

ABSTRACT:

Background

Lung cancer (LC) is one of the leading causes of death worldwide, which highlights the urgent need for better therapies. Peroxisome proliferator-activated nuclear receptor alpha (PPARα), known as a key nuclear transcription factor involved in glucose and lipid metabolism, has been also implicated in endothelial proliferation and angiogenesis. However, the effects and potential mechanisms of the novel PPARα ligand, AVE8134, on LC growth and progression remain unclear.

Methods

A subcutaneous tumour was established in mice by injecting TC-1 lung tumour cells (~ 1 × 10⁶ cells) into their shaved left flank. These mice were treated with three different PPARα ligands: AVE8134 (0.025% in drinking water), Wyeth-14,643 (0.025%), or Bezafibrate (0.3%). Tumour size

SUBMITTER: Wu L 

PROVIDER: S-EPMC6889744 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature